IGBA Impresses Importance Of Off-Patent Industry On WHO
CEO Advisory Committee Speaks Directly With WHO Leaders At October Meeting
The IGBA’s CEO advisory committee has met with WHO leaders, including director-general Tedros Adhanom Ghebreyesus, to impress upon them the importance of the generics and biosimilars industry in global patient care and the contribution made during the COVID-19 pandemic.
You may also be interested in...
In the first part of an exclusive three-part interview, Sandoz CEO Richard Saynor talks to Generics Bulletin about the firm’s upcoming separation from parent company Novartis, as well as outlining its unique position as a pure generics and biosimilars company among an evolving peer group of off-patent industry leaders.
The CEO advisory committee established by the IGBA has held its inaugural meeting and begun discussions with the director-general of the World Trade Organization to promote the “essential role” of generics and biosimilars in global health, with the interaction described as a first step towards a continuing dialog.
Leaders from a host of the world’s top generics and biosimilars companies have come together as part of a CEO advisory committee put together by the IGBA. The committee is expected to provide a forum to share thinking on key issues affecting the off-patent industry and best position the industry on critical policy issues with a single collective voice.